UK

In September 2023, NHS England defined the roadmap and key dates for the next version of the OPCS-4 nomenclature of procedures, which is updated every three years. The applications for changes can be submitted no later than December 1, 2024, to be implemented in the OPCS-4.11 version from April 2026.

The National Genomic Test Directory lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. It is updated annually. The applications submitted before April 1, 2024, to add new tests or change existing ones will be considered for implementation on April 1, 2025.

In August 2023, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease) and one new Diagnostic Guidance (quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care). Also, five clinical guidelines were updated.

In August 2023, the UK National Screening Committee (UK NSC) announced that the annual call for new topics is rescheduled. The next call will open from July 1 to September 30, 2024, and there will be no annual call in 2023. During the call, stakeholders can propose potential new screening programs or new technologies not yet considered by the UK NSC.

On August 10, 2023, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclatures for private payers in England, published Bulletins 191 and 087 with changes to be implemented no later than October 6, 2023. Five new procedure codes (concerning urogynecology, robotic surgery, and neuromodulation) and six new codes for in-vitro diagnostics were introduced.

In June 2023, one assessment was published by the Scottish Health Technologies Group (SHTG) concerning the review of clinical and cost-effectiveness evidence for a digital type 2 diabetes remission program in Scotland. Furthermore, six assessments are currently in development.

In August 2023, NHS England announced the first technology (AposHealth) that will be supported by the MedTech Funding Mandate (MTFM) in 2023/24. MTFM supports NICE-approved, clinically effective, and cost-saving medical devices, diagnostics, and digital technologies, making it mandatory for commissioners and providers to implement them.

In July 2023, Health Technology Wales completed one full appraisal on wearable cardioverter defibrillators with the publication of Evidence Appraisal Report (EAR) and Guidance. Furthermore, in July 2023, Health Technology Wales decided to proceed with a full appraisal of radiofrequency renal denervation in the treatment of resistant hypertension based on the published Topic Exploration Report.

In July 2023, the National Institute for Health and Care Research (NIHR) in England released one MedTech-related report in its Health Technology Assessment (HTA) Journal concerning MRI-based technologies for diagnosing non-alcoholic fatty liver disease. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

In June 2023, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (irreversible electroporation for treating prostate cancer) and one new Diagnostic Guidance (AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images). Also, three clinical guidelines were updated.

In June 2023, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (intraoperative electron beam radiotherapy, minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis, endoscopic ultrasound-guided gallbladder drainage, radiofrequency denervation for osteoarthritic knee pain, and Botulinum toxin type A injections into the urethral sphincter), two new Diagnostic Guidance (transperineal biopsy for prostate cancer, and FibroScan for liver fibrosis and cirrhosis), and two Medtech Innovation Briefings (MiraQ cardiac TTFM, Proov Confirm; their development started before April 2023). Also, four clinical guidelines were updated.

In June 2023, NHS England published two new specialized service specifications for pediatric photon radiotherapy and gender incongruence in children and young people. These documents define national standards for the provision of specialized services, including aims, outcomes, model of provision, patient pathway, inclusion criteria, and requirements for the facilities and staff.